SciELO - Scientific Electronic Library Online

 
vol.25 número3Enfoque de los factores de riesgo en lepra: un enfoque a partir de las determinantes sociales de la saludAvances recientes en el diagnóstico y tratamiento de la demencia vascular índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Medicas UIS

versión impresa ISSN 0121-0319

Resumen

ROJAS VILLABONA, Álvaro. How surgery, radiotherapy and chemotherapy each contribute to the outcome of treatment for adult patients with Glioblastoma?. Medicas UIS [online]. 2012, vol.25, n.3, pp.209-219. ISSN 0121-0319.

Introduction: glioblastoma is a common condition associated with high morbidity and mortality; most of newly diagnosed patients will die within two years. The current standard therapy is maximal surgical resection followed by radiotherapy plus concomitant and adjuvant temozolamide. Objective: it is the aim of this review to evaluate how determinant surgical resection, radiotherapy and chemotherapy are to the outcome of patients with glioblastoma. Methods: a literature search is done to identify trials evaluating the outcome of adults with glioblastoma after being treated with surgery, radiotherapy or chemotherapy. The Oxford Centre for Evidence-based Medicine Levels of Evidence model is used to grade the quality of the available evidence. Results: 18 articles, reporting results of 15 studies were included. Five trials evaluated the effect of surgery in survival. Surgical provides as much as 4.9 months benefit in overall survival in cases in which complete resection is possible. A systematic review and four clinical trials reported that radiotherapy increases the mean overall survival in a range from three to five months. The European organization for research and treatment of Cancer and The National Cancer Institute of Canada Clinical Trials Group (EORT-NCIC) described in 2005 an increase of the survival by two - three months on patients receiving concomitant and adjuvant TMZ compared to patients receiving radiotherapy alone. Addittion of a novel chemotherapeutic agent seems to improve the outcome of patients compared to the current standard of care. Conclusion: surgery, radiotherapy and chemotherapy, each have a modest effect in the outcome of adults with glioblastoma. (MÉD.UIS. 2012;25(3):209-19)

Palabras clave : Glioblastoma; General Surgery; Radiotherapy; Chemotherapy; Treatment Outcome.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )